Autolus Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 27, 2026
Autolus Therapeutics (Nasdaq: AUTL) will release fourth quarter and full year 2025 financial results and operational highlights before U.S. market open on March 27, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Autolus Therapeutics (Nasdaq: AUTL) will release fourth quarter and full year 2025 financial results and operational highlights before U.S. market open on March 27, 2026. Management will host a conference call and webcast at 8:30am EDT / 12:30pm GMT to discuss results and provide a business update.
Participants must pre-register to receive dial-in numbers and a personal PIN. A simultaneous audio webcast and replay will be available on the company events website.
Key Figures
- Earnings release date
- March 27, 2026
- Fourth quarter and full year 2025 results release before U.S. market open
- Conference call time EDT
- 8:30am EDT
- Management call to discuss 2025 financial results and business update
- Conference call time GMT
- 12:30pm GMT
- Simultaneous webcast for international investors
Historical Context
-
Announcement of participation in March 2026 investor conferences and webcasts.
-
Inducement stock options granted under Nasdaq Listing Rule 5635(c)(4).
-
Preliminary AUCATZYL 2025 revenue, 2026 guidance and positive margin/cash outlook.
-
Evaluation of Cellares Cell Shuttle platform to enhance CAR-T manufacturing capacity.
-
Updated Phase 1 CARLYSLE data for obe-cel in severe refractory systemic lupus.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
t cell therapies medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
LONDON and GAITHERSBURG, Md., March 16, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today announced that the Company will release its fourth quarter and full year 2025 financial results and operational highlights before open of U.S. markets on Friday, March 27, 2026.
Management will host a conference call and webcast at 8:30am EDT / 12:30pm GMT to discuss the company’s financial results and provide a general business update. Conference call participants should pre-register using this link to receive the dial-in numbers and a personal PIN, which are required to access the conference call.
A simultaneous audio webcast and replay will be accessible on the events section of Autolus’ website.
About Autolus Therapeutics plc
Autolus Therapeutics plc (Nasdaq: AUTL) is a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies and candidates for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, Autolus is engineering precisely targeted and controlled T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate these cells. Autolus has a marketed therapy, AUCATZYL®, and a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. For more information, please visit www.autolus.com.
Contact:
Amanda Cray
+1 617-967-0207
a.cray@autolus.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.